Genomics Core

项目总结/摘要 基因组学核心的目的是提供仪器，计算基础设施，技术和 分析专业知识和指导，以广泛启用和加强基因组分析在囊性 纤维化（CF）研究。在其他研究重点领域中，基因组学核心特别强调 了解CF个体中宿主-微生物的相互作用。核心的目标是：1）提供 测序和计算资源，以研究CF肠道中的微生物群落，2）提供 尖端的测序和计算资源，推动相关病原体的研究 与CF疾病状态，3）提供先进的服务，以了解基因表达和分子 与CF疾病状态相关的人类细胞的生理学，以及4）开发用于 CF微生物学的基因组规模分析。 这些目标将通过为UW CF研究人员提供咨询，生产和分析来实现。 与以下领域有关的服务： I.基因组学方法和实验设计咨询。 二.数据分析、数据管理和数据共享服务。 三.细菌全基因组测序。 四.宏基因组和16 S rRNA微生物组数据生成和分析。 V.转录组测序（RNA-Seq）和靶向基因表达分析（qRT-PCR）。 六.通过数字液滴PCR（dPCR）进行肠道微生物定量。 七.新的测序技术创新。 除了在不同时间点和不同疾病状态下定义肠道微生物组外， 对于患有CF的个人，核心将在推动项目中发挥主要作用，以确定如何在 胃肠道（GI）和呼吸道在CF患者的整个生命周期中发生变化，并了解 高效CFTR调节剂的施用如何改变 微生物组及其与宿主细胞的界面。

PROJECT SUMMARY/ABSTRACT The purpose of the Genomics Core is to provide instrumentation, computational infrastructure, technical and analytic expertise, and guidance in order to broadly enable and to enhance the use of genomic analysis in Cystic Fibrosis (CF) research. Among other areas of research focus, the Genomics Core places a special emphasis in understanding host-microbe interactions in individuals with CF. The Aims of the Core are to: 1) Provide sequencing and computational resources to study microbial communities in the CF gut, 2) Provide cutting-edge sequencing and computational resources that advance research on pathogens associated with CF disease states, 3) Provide advanced services to understand gene expression and molecular physiology of human cells that are relevant to CF disease states, and 4) Develop novel technologies for the genome-scale analysis of CF microbiology. These aims will be fulfilled by providing UW CF researchers with consultative, production, and analytical services relevant to the following domains: i. Consultation on genomic methods and experimental design. ii. Data Analysis, Data Management, and Data Sharing Services. iii. Bacterial whole genome sequencing. iv. Metagenomic and 16S rRNA Microbiome data generation and Analysis. v. Transcriptome sequencing (RNA-Seq) and targeted gene expression analysis (qRT-PCR). vi. Gut microbe quantitation by Digital Droplet PCR (dPCR). vii. New sequencing technology innovation. In addition to defining the microbiome of the gut at various timepoints and in various disease states of individuals with CF, the Core will play a primary role in driving projects to define how the microbiomes of the gastrointestinal (GI) and respiratory tracts change across the full lifespan of patients with CF, and to understand how the administration of highly effective CFTR modulators changes the composition and metabolic functions of the microbiome and its interface with host cells.